{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T01:49:53Z","timestamp":1781056193225,"version":"3.54.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","jpeds.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pediatrics"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.jpeds.2017.10.071","type":"journal-article","created":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T00:33:12Z","timestamp":1513816392000},"page":"128-135.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["New Onset Autoimmune Hepatitis during Anti-Tumor Necrosis Factor-Alpha Treatment in Children"],"prefix":"10.1016","volume":"194","author":[{"given":"Amanda","family":"Ricciuto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binita M.","family":"Kamath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas D.","family":"Walters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Frost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Carman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Church","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon C.","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpeds.2017.10.071_bib0010","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children","volume":"132","author":"Hyams","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jpeds.2017.10.071_bib0015","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1053\/j.gastro.2012.04.046","article-title":"Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children","volume":"143","author":"Hyams","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jpeds.2017.10.071_bib0020","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cgh.2011.11.026","article-title":"Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis","volume":"10","author":"Hyams","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jpeds.2017.10.071_bib0025","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/MCG.0000000000000696","article-title":"Biological therapy in pediatric inflammatory bowel disease: a systematic review","volume":"51","author":"Corica","year":"2017","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jpeds.2017.10.071_bib0030","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1053\/j.gastro.2017.02.004","article-title":"Infliximab is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease","volume":"152","author":"Hyams","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jpeds.2017.10.071_bib0035","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","article-title":"Causality assessment of adverse reactions to drugs\u2013I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries","volume":"46","author":"Danan","year":"1993","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jpeds.2017.10.071_bib0040","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/0895-4356(93)90102-7","article-title":"Causality assessment of adverse reactions to drugs\u2013II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge","volume":"46","author":"Benichou","year":"1993","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jpeds.2017.10.071_bib0045","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1002\/hep.22825","article-title":"Validation of simplified diagnostic criteria for autoimmune hepatitis in Italian patients","volume":"49","author":"Muratori","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jpeds.2017.10.071_bib0050","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1097\/MIB.0000000000000083","article-title":"Infliximab maintains durable response and facilitates catch-up growth in luminal pediatric Crohn's disease","volume":"20","author":"Church","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jpeds.2017.10.071_bib0055","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/MPG.0000000000001137","article-title":"Infliximab-associated immunomediated hepatitis in children with inflammatory bowel disease","volume":"63","author":"Mostamand","year":"2016","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jpeds.2017.10.071_bib0060","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.cgh.2012.12.025","article-title":"Liver injury from tumor necrosis factor-alpha antagonists: analysis of thirty-four cases","volume":"11","author":"Ghabril","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jpeds.2017.10.071_bib0065","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1055\/s-0034-1375959","article-title":"Drug-induced liver injury with autoimmune features","volume":"34","author":"deLemos","year":"2014","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jpeds.2017.10.071_bib0070","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1136\/ard.2004.032821","article-title":"Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis","volume":"64","author":"Germano","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jpeds.2017.10.071_bib0075","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/ibd.20230","article-title":"Occurrence of hepatoxicicty and elevated liver enzymes in a Crohn's disease patient treated with infliximab","volume":"13","author":"Moum","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jpeds.2017.10.071_bib0080","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.cgh.2014.07.062","article-title":"Risk of drug-induced liver injury from tumor necrosis factor antagonists","volume":"13","author":"Bjornsson","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jpeds.2017.10.071_bib0085","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/apt.13159","article-title":"New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease","volume":"41","author":"Shelton","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jpeds.2017.10.071_bib0090","doi-asserted-by":"crossref","first-page":"7584","DOI":"10.3748\/wjg.v21.i24.7584","article-title":"Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: a single center report of 8 cases","volume":"21","author":"Rodrigues","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jpeds.2017.10.071_bib0095","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/MEG.0000000000000624","article-title":"Elevated liver enzymes in inflammatory bowel disease: the role and safety of infliximab","volume":"28","author":"Parisi","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jpeds.2017.10.071_bib0100","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s10067-005-0169-y","article-title":"Serious liver disease induced by infliximab","volume":"26","author":"Tobon","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jpeds.2017.10.071_bib0105","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1136\/annrheumdis-2014-205318","article-title":"What is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single-centre cohort","volume":"73","author":"Takase","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jpeds.2017.10.071_bib0110","first-page":"58","article-title":"[Drug-induced liver injury with an autoimmune phenotype following anti-TNF Therapy - presentation of cases and review of literature]","volume":"52","author":"Rosner","year":"2014","journal-title":"Z Gastroenterol"},{"key":"10.1016\/j.jpeds.2017.10.071_bib0115","doi-asserted-by":"crossref","first-page":"344","DOI":"10.17235\/reed.2017.4258\/2016","article-title":"Autochthonous acute hepatitis E: an increasingly frequent diagnosis. Clinical-epidemiological analysis of our experience","volume":"109","author":"Monteserin Ron","year":"2017","journal-title":"Rev Esp Enferm Dig"}],"container-title":["The Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347617314919?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347617314919?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,25]],"date-time":"2018-08-25T00:55:53Z","timestamp":1535158553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022347617314919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":22,"alternative-id":["S0022347617314919"],"URL":"https:\/\/doi.org\/10.1016\/j.jpeds.2017.10.071","relation":{},"ISSN":["0022-3476"],"issn-type":[{"value":"0022-3476","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Onset Autoimmune Hepatitis during Anti-Tumor Necrosis Factor-Alpha Treatment in Children","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pediatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpeds.2017.10.071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}